Biomea Fusion is trading 5.5% up at $0.88, rebounding from its October 14 close of $0.83 after the prior session’s selloff. * The prior session's sharp decline was primarily driven by the announcement of an underwritten public offering of shares, which dilutes existing shareholders. * Phase 1 results for oral GLP-1 candidate BMF-650 were also announced on October 13, 2026, showing outpatient-cohort average weight loss of 1.5%–3.2% after 29 days, with the 6.1% confined-cohort result potentially affected by changes in eating behavior. * No new company-specific announcement or analyst action was identified for October 15 to explain today's rebound.